Evidence-Based Complementary and Alternative Medicine

Volume 2013 (2013), Article ID 748587, 5 pages

http://dx.doi.org/10.1155/2013/748587

Review Article

Targeting Sonic Hedgehog Signaling by Compounds and Derivatives from Natural Products

Yu-Chuen Huang,1,2,3 K. S. Clifford Chao,⁴ Hui-Fen Liao,⁵ and Yu-Jen Chen6,7

¹School of Chinese Medicine, China Medical University, Taichung 404, Taiwan

²Graduate Institute of Biostatistics, China Medical University, Taichung 404, Taiwan

³Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan

⁴Department of Radiation Oncology, Columbia University, New York, NY 10032, USA

⁵Department of Biochemical Science and Technology, National Chiayi University, Chiayi 600, Taiwan

⁶Institute of Traditional Medicine, National Yang-Ming University, Taipei 112, Taiwan

⁷Department of Radiation Oncology and Department of Medical Research, Mackay Memorial Hospital, 92 Chung-Shan North Road, Section 2, Taipei 104, Taiwan

Received 25 February 2013; Accepted 30 April 2013

Academic Editor: Min Shen Chang

Copyright © 2013 Yu-Chuen Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Cancer stem cells (CSCs) are a major cause of cancer treatment failure, relapse, and drug resistance and are known to be responsible for cancer cell invasion and metastasis. The Sonic hedgehog (Shh) signaling pathway is crucial to embryonic development. Intriguingly, the aberrant activation of the Shh pathway plays critical roles in developing CSCs and leads to angiogenesis, migration, invasion, and metastasis. Natural compounds and chemical structure modified derivatives from complementary and alternative medicine have received increasing attention as cancer chemopreventives, and their antitumor effects have been demonstrated both in vitro and in vivo. However, reports for their bioactivity against CSCs and specifically targeting Shh signaling remain limited. In this review, we summarize investigations of the compounds cyclopamine, curcumin, epigallocatechin-3-gallate, genistein, resveratrol, zerumbone, norcantharidin, and arsenic trioxide, with a focus on Shh signaling blockade. Given that Shh signaling antagonism has been clinically proven as effective strategy against CSCs, this review may be exploitable for development of novel anticancer agents from complementary and alternative medicine.

1. Introduction

Cancer stem cells (CSCs) are a small minority of cancer cells that can proliferate extensively and form new tumors [1–4]. These properties of CSCs are thought to cause cancer treatment failure, relapse, and drug resistance [5]. As with normal stem cells, CSCs are self-renewing and can differentiate into phenotypically diverse tumor and nontumor cancer cells [2]. Several embryonic signaling pathways are known to be involved in normal stem cell maintenance, and these have recently been linked to carcinogenesis and tumor propagation. Indeed, signaling pathways that support dysregulated self-renewal and proliferation of CSCs may provide practical targets for preventing tumor regrowth and improving treatment outcomes.

Sonic hedgehog (Shh) signaling is critical to embryogenesis and is essential for the development of several tissue types and organs [6]. Aberrant activation of Shh signaling is central to CSC activities, which promotes tumor progression, angiogenesis, migration, invasion, and metastasis [7–9]. Dysregulation of Shh signaling has been involved with several malignancies, including basal cell carcinomas, medulloblastomas, leukemia, oral squamous cell carcinomas, and gastrointestinal, pancreas, lung, ovarian, breast, and prostate cancers [10–14]. Shh is a secreted glycoprotein that activates signaling by binding to the transmembrane receptor patched-1 (Ptch1). Subsequently, Ptch1-mediated inactivation of Smoothened (Smo) is reversed, allowing transduction of the Shh signal, which results in nuclear translocation of cytoplasmic transcription factors of the Gli family to modulate target gene expression [15].

Since CSCs are considered as a cause of cancer treatment failure, relapse, and drug resistance, therapeutic targeting of CSCs may overcome tumor resistance, reduce relapse, and improve patient survival. The small molecule Smo inhibitor vismodegib has been demonstrated effective in reducing the basal-cell carcinoma tumor burden. However, the adverse events caused discontinuation in over half of treated patients [16]. It implicates that Shh signaling blockade is an effective strategy and remains a room to develop effective agents with more favorable safety profile. Several naturally occurring dietary compounds have shown promise as Shh signaling inhibitors. In this paper, we review the current understanding of some natural compounds that have cancer treatment potential, with a focus on targeting the Shh signaling pathway (Figure 1).

Figure 1: Targeting the Sonic hedgehog signaling pathway by compounds and derivatives from natural products. Circled numbers beside compound names indicate target Shh signaling proteins. Question marks indicate that the targeted protein is uncertain.

2. Compounds and Derivatives from Natural Products That Regulate Sonic Hedgehog Signaling Pathway

2.1. Cyclopamine

Cyclopamine is a naturally occurring compound from the plant Veratrum californicum, commonly known as corn lily, and was the first phytochemical, which demonstrated Shh pathway inhibitory activity [17, 18], and was shown to block the activation of Smo [18]. Berman et al. reported that treatment of murine medulloblastoma cells with cyclopamine inhibited proliferation, induced neuronal differentiation, and depleted CSC populations [17]. It also caused regression of murine tumor allografts and induced rapid death of cells from freshly resected human medulloblastomas [17]. Cyclopamine may inhibit development and invasiveness of human hepatocellular carcinomas (HCCs) in vitro and in vivo by inhibiting the Shh pathway. Blockade of Shh signaling may be a potential target of new therapeutic strategy for HCC [19–22]. In addition, cyclopamine effectively targeted CSCs of pancreatic cancer, breast cancer, glioblastoma, and multiple myeloma [23, 24].

2.2. Curcumin

Curcumin, the major extract of tumeric, is derived from the plant Curcuma longa, which is a common ingredient of mustard and curry [25, 26]. It has been widely used in traditional medicines and dietary supplements for centuries [27]. Curcumin has anti-inflammatory and antioxidant activities and has been studied as a preventive agent in several cancer models [25, 28]. After treating medulloblastoma cells with curcumin, Elamin et al. observed that curcumin caused inhibition of Shh signaling cell growth and induction of apoptotic cell death by downregulating proteins of the Shh pathway. In addition, curcumin enhanced the antitumor effects of cisplatin and γ-rays by targeting pathways that are crucial for tumor survival [29]. Moreover, curcumin inhibited prostate cancer cell growth through the Shh pathway and reduced or delayed prostate cancer growth in a transgenic adenocarcinoma mouse model [30].

2.3. Epigallocatechin-3-Gallate

Green tea is one of the most widely consumed beverages in the world [31]. Epigallocatechin-3-gallate (EGCG) acts as a potent cancer-preventive agent through various mechanisms and is the most abundant polyphenolic catechin in green tea [32]. Specifically, Tang et al. reported inhibition of the Shh pathway, induction of apoptosis, and suppression of human chondrosarcoma cell proliferation by EGCG, suggesting that EGCG could be a new therapeutic agent for patients with chondrosarcoma [33]. Moreover, EGCG was shown to inhibit prostate cancer cell growth by suppressing Gli1 mRNA expression and downregulating Gli promoter activity [30]. In transgenic prostate adenocarcinoma mice, EGCG reduced or delayed prostate tumor growth [30]. A recent report showed that EGCG inhibited the components of Shh pathway and Gli transcriptional activity in pancreatic CSCs. It also inhibited self-renewal capacity of pancreatic CSCs, and these effects were enhanced in the presence of the flavonoid quercetin, which is present in fruits and vegetables such as onion, tea, apples, and berries [11]. These data suggest that EGCG either alone or in combination with quercetin could be used to prevent and treat pancreatic cancer [11].

2.4. Isoflavone Genistein

Soybeans are an abundant source of isoflavones. Genistein is one of the most active soy isoflavones. Numerous studies report protective effects of soy foods against breast and prostate cancers [34–37]. Indeed, soy isoflavones, particularly genistein, exert potent antiproliferative effects on breast, prostate, colon, skin, gastric, and bladder cancers [38]. In transgenic prostate adenocarcinoma mice, genistein inhibited cancer cell growth through its actions on the Shh pathway and reduced or delayed growth of prostate tumors [30]. In a study by Zhang et al., genistein not only inhibited prostate cancer cell invasion [39] but also targeted prostate CSCs and suppressed tumorigenicity [40]. This anti-CSC effect was due to inhibition of the Shh protein Gli1 [40], suggesting that genistein may be a potent chemopreventive agent against prostate CSCs.

2.5. Resveratrol

Resveratrol is a dietary polyphenol derived from plants such as grapes, berries, plums, peanuts, and Polygonum cuspidatum [41]. Resveratrol inhibited the proliferation of a wide variety of human cancer cells in vitro and slowed carcinogenesis in animal models [42, 43], suggesting therapeutic and cancer preventive effects [43]. Ślusarz et al. demonstrated involvement of Shh signaling in resveratrol-mediated inhibition of prostate cancer cell growth in vitro and in vivo [30]. Moreover, resveratrol inhibited both Shh signaling and Bcr-Abl expression in human chronic myeloid leukemia (CML) cells, indicating that resveratrol may have potential as a treatment for CML [10]. Recently, another report showed that resveratrol could effectively downregulate interleukin-6-stimulated Shh signaling in human acute myeloid leukemia [44].

2.6. Zerumbone

Zingiber zerumbet Smith is a perennial, tuberous root herb that grows mainly in southeast Asia [45]. The major extract zerumbone has been shown to increase apoptosis and inhibit cancer cell invasion and has demonstrated antitumor effects against leukemia and breast, lung, liver, and pancreatic cancers [46–49]. Hosoya et al. reported that zerumbone inhibited both Gli1- and Gli2-mediated transcription and repressed the transcription of other Shh signaling genes, including Ptch1 and BCL2, in HaCaT cells [50].

2.7. Norcantharidin

The small-molecule norcantharidin (NCTD) is a demethylated synthetic analog of naturally occurring cantharidin from blister beetles (Mylabris phalerata Pall.). The effects of NCTD against diverse malignancies have been investigated. It has been shown capable of inducing cell anoikis and apoptosis [51], inhibiting invasion and angiogenesis [52], and suppressing metastasis [53]. Moreover, NCTD may overcome multidrug resistance by inhibiting Shh signaling and expression of downstream multidrug resistance (MDR1) P-glycoprotein in human breast cancer cells [13].

2.8. Arsenic Trioxide

Arsenic trioxide (As₂O₃) has been used therapeutically in traditional Chinese medicine for a long time and has been shown as a highly effective treatment for relapsed acute promyelocytic leukemia [54]. In addition, arsenic trioxide can inhibit Shh signaling at the Gli protein level, although the exact mechanism remains controversial. Kim et al. demonstrated that arsenic trioxide antagonizes Shh signaling primarily through interference with Gli2 [55]. Moreover, Beauchamp and colleagues provide evidence that arsenic trioxide could inhibit the growth of Ewing sarcoma and medulloblastoma cells by targeting Gli1 [56]. These data suggest that arsenic trioxide could be used as a therapeutic agent in malignant diseases associated with Shh pathway activation.

2.9. Clinical Implications of Natural Compounds and Derivatives

Some natural compounds and their derivatives have potent antitumor effects, offering clues to the design of targeted therapeutic anticancer agents. In addition to affecting cancer related signaling pathways, natural compounds may synergize with chemotherapy and radiotherapy as antitumor agents. For example, Choi et al. showed pretreatment with zerumbone before radiation induced radiosensitization in human lung adenocarcinoma cells and in a xenograft mice model [57]. Curcumin, genistein, and EGCG have potential in the treatment of prostate cancer [30, 39, 40]. Moreover, resveratrol and NCTD are potential treatments for acute myeloid leukemia and breast cancer, respectively [13, 44]. Hence, further development of molecular tests that assess tumor tissue and DNA from patients will aid therapeutic decisions to use natural compounds. In addition, molecular markers of Shh signaling may facilitate the development of personalized cancer treatments.

3. Conclusions

In conclusion, the antitumor effects of naturally occurring compounds that target Shh signaling indicate the importance of this pathway to cancer cell invasion and metastasis. Hence, these natural compounds and related derivatives may be used as primary treatment or as adjunctive agents for combinatory treatment to improve therapeutic index against cancer. Although this review focuses only on natural compounds and related derivatives that target the Shh signaling pathway, the data summarized herein indicate that complementary and alternative medicine may comprise a multitude of compounds with potential to prevent cancer and its metastasis by targeting various signaling pathways. Further in vitro and in vivo studies, as well as clinical trials, are warranted to investigate the therapeutic potential of natural compounds against CSCs.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This study is supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004), China Medical University, Taichung, Taiwan (CMU100-N1-08-1), and the National Science Council, Taipei, Taiwan (NSC101-2314-B-039-024, 100-2314-B-195-007-MY3, and 98–2314-B-195-005-MY3).

References

H. D. Hemmati, I. Nakano, J. A. Lazareff et al., “Cancerous stem cells can arise from pediatric brain tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178–15183, 2003.

M. Al-Hajj and M. F. Clarke, “Self-renewal and solid tumor stem cells,” Oncogene, vol. 23, no. 43, pp. 7274–7282, 2004.

M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003.

J. Marx, “Mutant stem cells may seed cancer,” Science, vol. 301, no. 5638, pp. 1308–1310, 2003.

R. J. Jones, W. H. Matsui, and B. D. Smith, “Cancer stem cells: are we missing the target?” Journal of the National Cancer Institute, vol. 96, no. 8, pp. 583–585, 2004.

M. Varjosalo and J. Taipale, “Hedgehog: functions and mechanisms,” Genes and Development, vol. 22, no. 18, pp. 2454–2472, 2008.

M. Rodova, J. Fu, D. N. Watkins, R. K. Srivastava, and S. Shankar, “Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal,” PLoS One, vol. 7, no. 9, Article ID e46083, 2012.

Y. J. Chen, J. Sims-Mourtada, J. Izzo, and K. S. C. Chao, “Targeting the hedgehog pathway to mitigate treatment resistance,” Cell Cycle, vol. 6, no. 15, pp. 1826–1830, 2007.

R. L. Carpenter and H. W. Lo, “Hedgehog pathway and GLI1 isoforms in human cancer,” Discovery Medicine, vol. 13, no. 69, pp. 105–113, 2012.

H. F. Liao, Y. C. Su, Z. Y. Zheng, et al., “Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells,” Biomedicine and Pharmacotherapy, vol. 66, no. 5, pp. 378–383, 2012.

S. N. Tang, J. Fu, D. Nall, M. Rodova, S. Shankar, and R. K. Srivastava, “Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics,” International Journal of Cancer, vol. 131, no. 1, pp. 30–40, 2012.

L. Yang, G. Xie, Q. Fan, and J. Xie, “Activation of the hedgehog-signaling pathway in human cancer and the clinical implications,” Oncogene, vol. 29, no. 4, pp. 469–481, 2010.

Y. J. Chen, C. D. Kuo, S. H. Chen, et al., “Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells,” PLoS One, vol. 7, no. 5, Article ID e37006, 2012.

Y. F. Wang, C. J. Chang, C. P. Lin, et al., “Expression of hedgehog signaling molecules as a prognostic indicator of oral squamous cell carcinoma,” Head and Neck, vol. 34, no. 11, pp. 1556–1561, 2012.

Y. Z. Feng, T. Shiozawa, T. Miyamoto et al., “Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells,” Clinical Cancer Research, vol. 13, no. 5, pp. 1389–1398, 2007.

J. Y. Tang, J. M. kay-Wiggan, M. Aszterbaum, et al., “Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome,” The New England Journal of Medicine, vol. 366, no. 23, pp. 2180–2188, 2012.

D. M. Berman, S. S. Karhadkar, A. R. Hallahan et al., “Medulloblastoma growth inhibition by Hedgehog pathway blockade,” Science, vol. 297, no. 5586, pp. 1559–1561, 2002.

J. K. Chen, J. Taipale, M. K. Cooper, and P. A. Beachy, “Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened,” Genes and Development, vol. 16, no. 21, pp. 2743–2748, 2002.

K. S. Jeng, I. S. Sheen, W. J. Jeng, et al., “Blockade of the sonic hedgehog pathway effectively inhibits the growth of hepatoma in mice: an in vivo study,” Oncology Letters., vol. 4, no. 6, pp. 1158–1162, 2012.

X. L. Chen, Q. Y. Cheng, M. R. She et al., “Expression of Sonic Hedgehog signaling components in hepatocellular carcinoma and cyclopamine-induced apoptosis through Bcl-2 downregulation in vitro,” Archives of Medical Research, vol. 41, no. 5, pp. 315–323, 2010.

W. T. Cheng, K. Xu, D. Y. Tian, Z. G. Zhang, L. J. Liu, and Y. Chen, “Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells,” International Journal of Oncology, vol. 34, no. 3, pp. 829–836, 2009.

Y. Kim, W. Y. Joon, X. Xiao, N. M. Dean, B. P. Monia, and E. G. Marcusson, “Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells,” Cancer Research, vol. 67, no. 8, pp. 3583–3593, 2007.

E. E. Bar, A. Chaudhry, A. Lin et al., “Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma,” Stem Cells, vol. 25, no. 10, pp. 2524–2533, 2007.

D. Subramaniam, S. Ramalingam, C. W. Houchen, and S. Anant, “Cancer stem cells: a novel paradigm for cancer prevention and treatment,” Mini Reviews in Medicinal Chemistry, vol. 10, no. 5, pp. 359–371, 2010.

Y. Li, M. S. Wicha, S. J. Schwartz, and D. Sun, “Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds,” Journal of Nutritional Biochemistry, vol. 22, no. 9, pp. 799–806, 2011.

C.H. Park, E.R. Hahm, S. Park, H.K. Kim, and C.H. Yang, “The inhibitory mechanism of curcumin and its derivative against β-catenin/Tcf signaling,” FEBS Letters, vol. 579, no. 13, pp. 2965–2971, 2005.

B. B. Aggarwal, C. Sundaram, N. Malani, and H. Ichikawa, “Curcumin: the Indian solid gold,” Advances in Experimental Medicine and Biology, vol. 595, pp. 1–75, 2007.

Z. M. Shao, Z. Z. Shen, C. H. Liu et al., “Curcumin exerts multiple suppressive effects on human breast carcinoma cells,” International Journal of Cancer, vol. 98, no. 2, pp. 234–240, 2002.

M. H. Elamin, Z. Shinwari, S. F. Hendrayani et al., “Curcumin inhibits the sonic hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells,” Molecular Carcinogenesis, vol. 49, no. 3, pp. 302–314, 2010.

A. Ślusarz, N. S. Shenouda, M. S. Sakla et al., “Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer,” Cancer Research, vol. 70, no. 8, pp. 3382–3390, 2010.

H. N. Graham, “Green tea composition, consumption, and polyphenol chemistry,” Preventive Medicine, vol. 21, no. 3, pp. 334–350, 1992.

H. Fujiki, “Two stages of cancer prevention with green tea,” Journal of Cancer Research and Clinical Oncology, vol. 125, no. 11, pp. 589–597, 1999.

G. Q. Tang, T. Q. Yan, W. Guo et al., “(-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 8, pp. 1179–1185, 2010.

J. R. Hebert, T. G. Hurley, B. C. Olendzki, J. Teas, Y. Ma, and J. S. Hampl, “Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study,” Journal of the National Cancer Institute, vol. 90, no. 21, pp. 1637–1647, 1998.

M. Verheus, C. H. van Gils, L. Keinan-Boker, P. B. Grace, S. A. Bingham, and P. H. M. Peeters, “Plasma phytoestrogens and subsequent breast cancer risk,” Journal of Clinical Oncology, vol. 25, no. 6, pp. 648–655, 2007.

H. Adlercreutz, H. Markkanen, and S. Watanabe, “Plasma concentrations of phyto-oestrogens in Japanese men,” The Lancet, vol. 342, no. 8881, pp. 1209–1210, 1993.

M. Iwasaki, M. Inoue, T. Otani et al., “Plasma isoflavone level and subsequent risk of breast cancer among japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1677–1683, 2008.

S. Barnes, “Effect of genistein on in vitro and in vivo models of cancer,” Journal of Nutrition, vol. 125, no. 3, supplement, pp. 777S–783S, 1995.

L. L. Zhang, L. Li, D. P. Wu et al., “A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells,” Acta Pharmacologica Sinica, vol. 29, no. 9, pp. 1060–1068, 2008.

L. Zhang, L. Li, M. Jiao, et al., “Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway,” Cancer Letters, vol. 323, no. 1, pp. 48–57, 2012.

K. B. Harikumar and B. B. Aggarwal, “Resveratrol: a multitargeted agent for age-associated chronic diseases,” Cell Cycle, vol. 7, no. 8, pp. 1020–1037, 2008.

A. Bishayee, “Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials,” Cancer Prevention Research, vol. 2, no. 5, pp. 409–418, 2009.

B. B. Aggarwal, A. Bhardwaj, R. S. Aggarwal, N. P. Seeram, S. Shishodia, and Y. Takada, “Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies,” Anticancer Research, vol. 24, no. 5 A, pp. 2783–2840, 2004.

Y. C. Su, S. C. Li, Y. C. Wu, L. M. Wang, K. S. Chao, and H. F. Liao, “Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 547430, 11 pages, 2013.

S. Zhang, Q. Liu, Y. Liu, H. Qiao, and Y. Liu, “Zerumbone, a southeast Asian Ginger Sesquiterpene, induced apoptosis of pancreatic carcinoma cells through p53 signaling pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 936030, 8 pages, 2012.

M. Xian, K. Ito, T. Nakazato et al., “Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle arrest and apoptosis in leukemia cells via a Fas- and mitochondria-mediated pathway,” Cancer Science, vol. 98, no. 1, pp. 118–126, 2007.

M. Kim, S. Miyamoto, Y. Yasui, T. Oyama, A. Murakami, and T. Tanaka, “Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice,” International Journal of Cancer, vol. 124, no. 2, pp. 264–271, 2009.

S. A. S. Sakinah, S. T. Handayani, and L. P. A. Hawariah, “Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio,” Cancer Cell International, vol. 7, article 4, 2007.

B. Sung, S. Jhurani, S. A. Kwang et al., “Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells,” Cancer Research, vol. 68, no. 21, pp. 8938–8944, 2008.

T. Hosoya, M. A. Arai, T. Koyano, T. Kowithayakorn, and M. Ishibashi, “Naturally occurring small-molecule inhibitors of Hedgehog/GLI-mediated transcription,” ChemBioChem, vol. 9, no. 7, pp. 1082–1092, 2008.

Y. J. Chen, C. D. Kuo, Y. M. Tsai, C. C. Yu, G. S. Wang, and H. F. Liao, “Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells,” Anti-Cancer Drugs, vol. 19, no. 1, pp. 55–64, 2008.

Y. J. Chen, Y. M. Tsai, C. D. Kuo, K. L. Ku, H. S. Shie, and H. F. Liao, “Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect,” Life Sciences, vol. 85, no. 17-18, pp. 642–651, 2009.

Y. J. Chen, W. M. Chang, Y. W. Liu et al., “A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells,” Chemico-Biological Interactions, vol. 181, no. 3, pp. 440–446, 2009.

B. L. Powell, “Arsenic trioxide in acute promyelocytic leukemia: potion not poison,” Expert Review of Anticancer Therapy, vol. 11, no. 9, pp. 1317–1319, 2011.

J. Kim, J. J. Lee, J. Kim, D. Gardner, and P. A. Beachy, “Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 30, pp. 13432–13437, 2010.

E. M. Beauchamp, L. Ringer, G. Bulut et al., “Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway,” Journal of Clinical Investigation, vol. 121, no. 1, pp. 148–160, 2011.

S. H. Choi, Y. J. Lee, W. D. Seo et al., “Altered cross-linking of HSP27 by Zerumbone as a novel strategy for overcoming HSP27-mediated radioresistance,” International Journal of Radiation Oncology Biology Physics, vol. 79, no. 4, pp. 1196–1205, 2011.